Clinical trials: Nonalcoholic Fatty Liver
Nonalcoholic Fatty Liver
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
- Trial name
- NCT03763877
- Testing
- PXL770
- Where
- 15 sites in United States
- Volunteers
- 121 people
- Sponsor
- Poxel SA
Non-alcoholic Steatohepatitis
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients with biopsy-proven non-alcoholic steatohepatitis.
- Trial name
- NCT02541045
- Testing
- metadoxine
- Where
- Mexico
- Sponsor
- Hospital General de Mexico
Non-alcoholic Fatty Liver Disease
Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)
In peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory M1 and anti-inflammatory M2 phenotypes.
- Trial name
- NCT01472120
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
NAFLD
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, which is one of the most common forms of chronic liver disease in developed countries.
- Trial name
- NCT02083159
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Korea University
Non-Alcoholic Fatty Liver Disease, Obesity
Sulforaphane Supplementation Study
Non-alcoholic fatty liver disease (NAFLD) is increasing in the population, and is associated with heart disease and diabetes. At present there are no licensed drugs for treatment of NAFLD, therefore changes in diet and increased…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- FAMOUS (NCT04364360)
- Testing
- Sulforaphane extract
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Nonalcoholic Fatty Liver Disease (NAFLD)
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs.
- Trial name
- NF-NAFLD (NCT02213224)
- Testing
- Perindopril, Telmisartan, Amlodipine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nonalcoholic Fatty Liver Disease
Role of Exenatide in NASH-a Pilot Study
We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.
- Trial name
- NAFLD (NCT00650546)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
NASH - Nonalcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks.
- Trial name
- NCT04697810
- Testing
- Namodenoson
- Where
- 24 sites in Bosnia and Herzegovina, Bulgaria and 4 more
- Volunteers
- 114 people
- Sponsor
- Can-Fite BioPharma
Obesity, Gastric Bypass
Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery
Aim of this prospective randomized intervention study is to evaluate the effect of a dietary intervention with a specific micronutrient-probiotic-combination for 12 weeks on fatty liver and cardiometabolic status in obese…
- Conditions
- Obesity, Gastric Bypass, NAFLD
- Trial name
- FMG-01 (NCT03585413)
- Testing
- Micronutrient-probiotic-combination
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Bonn Education Association for Dietetics r.A., Cologne, Germany
Non-alcoholic Steatohepatitis
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
- Trial name
- NCT06105060
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 175 people
- Sponsor
- Beni-Suef University
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
DIABETES MELLITUS
The Effect of Vitamin D Supplementation in Type 2 Diabetes
In many observational studies, vitamin D deficiency is related to glucose intolerance and diabetes. But there little randomized, controlled interventional studies that evaluate the effect of vitamin D in type 2 diabetes.
- Trial name
- VD2000 (NCT01854463)
- Testing
- Vitamin D3
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
NASH - Nonalcoholic Steatohepatitis
Phase 2a Study of HPG1860 in Subjects With NASH
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
- Trial name
- RISE (NCT05338034)
- Testing
- HPG1860
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Hepagene (Shanghai) Co., Ltd.
NAFLD, Overweight and Obesity
The Acute Effects of Eucaloric and Hypocaloric Carbohydrate Restriction on Liver Fat Content and Metabolism in Obese Individuals
The primary aim of this study is to investigate the acute changes in liver fat content in response to a fixed carbohydrate restriction (i.e.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- FixedCarb (NCT05643521)
- Testing
- Dietary composition of macronutrients and calories
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients)…
- Trial name
- NCT05084404
- Testing
- Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Yokohama City University
NASH - Nonalcoholic Steatohepatitis
Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
The aim of the present study is to evaluate the efficacy and safety of pentoxifylline in the treatment of non-alcoholic steatohepatitis patients.
- Trial name
- NCT05284448
- Testing
- pentoxifylline (Trental SR®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Obesity, Non-Alcoholic Fatty Liver Disease
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
- Trial name
- ATM (NCT06571474)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Non Alcoholic Fatty Liver Disease
Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial
Now considered as a major public health challenge, non-alcoholic fatty liver disease (NAFLD) is rapidly rising as a major cause of end-stage liver disease.
- Trial name
- S@VE-LIVER (NCT07497750)
- Testing
- Fibroscan CAP/VTE, Randomization, MRI-PDFF
- Where
- 9 sites in France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.